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Background: Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML), which accounts
for approximately 10% of all acute myloid leukemia cases. It is a blood cancer that is formed by chromosomal
mutation. Each year in the United States, APL affects about 1,500 patients of all age groups and causes
approximately 1.2% of cancer deaths. Arsenic trioxide (ATO) has been used successfully for treatment of APL
patients, and both induction and consolidated therapy have resulted in complete remission. Recently published
studies from our laboratory have demonstrated that ATO pharmacology as an anti-leukemic drug is associated with
cytotoxic and genotoxic effects in leukemia cells.
Methods: In the present study, we further investigated the detailed molecular mechanism of ATO-mediated
intrinsic pathway of apoptosis; using HL-60 cells as a test model. Oxidative stress was assessed by spectrophotometric
measurements of MDA and GSH levels while genotoxicity was determined by single cell gel electrophoresis
(Comet assay). Apoptosis pathway was analyzed by Western blot analysis of Bax, Bcl2 and caspase 3 expression, as
well as immunocytochemistry and confocal imaging of Bax and Cyt c translocation and mitochondrial membrane
potential depolarization.
Results: ATO significantly (p < 0.05) induces oxidative stress, DNA damage, and caspase 3 activityin HL-60 cells in a
dose-dependent manner. It also activated the intrinsic pathway of apoptosis by significantly modulating (p < 0.05)
the expression and translocation of apoptotic molecules and decreasing the mitochondrial membrane potential in
leukemia cells.
Conclusion: Taken together, our research demonstrated that ATO induces mitochondrial pathway of apoptosis in
HL-60 cells. This apoptotic signaling is modulated via oxidative stress, DNA damage, and change in mitochondrial
membrane potential, translocation and upregulation of apoptotic proteins leading programmed cell death.
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Acute promyelocytic leukemia (APL) is a subtype of acute
myeloid leukemia (AML), which causes approximately
1.2% of cancer deaths in USA [1,2]. APL is a blood cancer
that affects all age groups of people and strikes about
1,500 patients in the United States each year [3]. Initially,
APL was treated with conventional chemotherapy method
by using cytarabine and daunorubicin to achieve complete* Correspondence: paul.b.tchounwou@jsums.edu
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unless otherwise stated.remissions (CRs) in approximately 70% of patients having
5-year disease-free survival of 35–45% [4,5]. All trans ret-
inoic acid (ATRA) has brought revolutionary change for
APL patients treatment. Combination of ATRA plus an
anthracycline, with or without cytarabine achieved remis-
sion rates of nearly 90% for APL patients [1]. Although
many therapeutic advances such as combined chemother-
apy and hematopoietic stem cell transplantation have been
made to improve the survival rate of APL patients, a
higher proportion of patients relapse and hence do not
undergo complete remission. Also, because of the growing
evidence of resistance to ATRA treatment of APL patientsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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proved arsenic trioxide (ATO) for APL patient treatment
in September 2000 on the basis of several human clinical
trials showing very promising results [7].
ATO is a drug of choice for the treatment of both re-
lapsed and refractory APL patients. It is used alone or
combination with all trans retinoic acid (ATRA) to achieve
complete remission and maximum survival rate [8,9].
Existing evidence has shown that APL patients treated with
ATO achieved complete remission with high survival rate
without ATRA combination [10]. In a Phase II clinical trial
study, it was reported that these APL patients treated with
ATO alone observed a high rate of 5-years disease free sur-
vival (DFS) and an overall survival (OS) [11]. Few reports
have suggested that ATO inhibits proliferation of human
myeloma cells by cell cycle arrest [12] and induces apop-
tosis in HL-60 cells by phosphotidylserine externalization
as well as DNA laddering [3].
ATO is a clastogenic/genotoxic compound. It has been
shown to induce DNA damage/mutation in cultured mouse
lymphoma cells [13] and bone marrow cells of Sprague–
Dawley rats [14]. It induces DNA damage through double
strands break in human colon cancer cells [15] and also
DNA fragmentation as well as p53 activation in gastric
cancer cells [16]. ATO also modulates stress gene (p53) ex-
pression in human liver carcinoma cells (HepG2) [17].
Although the detailed molecular mechanisms of the
anti-cancer potency of ATO are not well understood, it
has been shown to induce oxidative stress in hepatocel-
lular carcinoma cells [18] and apoptosis in leukemia as
well myeloma cells [19,20]. It has also been reported to
induce apoptosis in cancer cells through cell cycle arrest
[21] and modulation of apoptotic genes expression in NB4
cells [22]. ATO has also been shown to induce mitotic ar-
rest and apoptosis in NB4 cells by changing mitochondrial
membrane potential [23]. However, the detailed molecular
mechanisms of ATO-induced oxidative stress, genotoxi-
city, and intrinsic pathway of apoptosis in HL-60 cells are
not well elucidated. Therefore, in the present study, we in-
vestigated ATO–induced oxidative and genotoxic stress
and its resulting impact on specific biomarkers of the
mitochondrial pathway of apoptosis inhuman leukemia
(HL-60) cells. HL-60 cell line has been derived from per-
ipheral blood leukocytes of a patient with acute promyelo-
cytic leukemia [24].
Methods
Cell line and culture
The APL cell line used in this study was HL-60. The
Cells were purchased from the American Type Culture
Collection (Manassas, VA), and maintained at 37°C in an
atmosphere of 5% CO2 and 95% air according to standard
procedures. HL-60 cells were cultured in Iscove’s Modified
Dulbecco’s Medium (IMDM) containing 10% fetal bovineSerum (FBS) and 1% penicillin-streptomycin solution with
cell density, 2×105 viable cells/ml. 5×107 cells were seeded
for each dose of arsenic trioxide and incubated 24 hour at
37°C inside C02 incubator.
Chemicals and reagents
ATO was purchased from Fischer Scientific (Pittsburgh,
PA). Mitochondrial isolation kit, Caspase assay kit, pro-
tease inhibitor and Glutathione assay kit were obtained
from Sigma-Aldrich (St. Louis, MO). Anti-Cytochrome C,
anti-Bax and anti-Bcl2 were purchased by Cell Signaling
Technology (Danvers, MA). Lipid peroxidation kit and
caspase 3 kit were obtained from Abcam (Cambridge,
MA). Mitotracker red, Hoechst 33342, Alexa fluor 568
and Alexa fluor 568 were purchased from Life Technolo-
gies (Grand Island/NY).
Measurement of reduced GSH
Leukemia cells were grown in presence or absence of
ATO and the GSH content inside the cytoplasm was
measured following a previously published protocol [25].
Lipid peroxidation assay
HL-60 cells were treated with or without ATO and lipid
peroxidation was evaluated by measuring malondialde-
hyde (MDA) levels using the lipid peroxidation assay kit
(Abcam) as previously described [25].
Single cell gel electrophoresis (Comet) assay
HL-60 cells were cultured in presence or absence of ATO
and DNA damage was analyzed by performing a very sen-
sitive alkaline comet assay as previously described [26],
with few modifications in our laboratory [27,28]. The
whole process was carried out under yellow light in order
to minimize UV light damage. Agarose was prepared
through melting in a boiling water bath and allowing it to
return to room temperature. The cells were mixed with
the melted agarose in a 1:10 ratio. Approximately 75 μL of
the mixture of agarose and cells were placed on comet
slides, and the agarose was solidified at 4°C for 10 min.
After 10 min, the slides were placed in a lysis solution at
4°C for 30 min to lyse the embedded cells in the agarose.
The excess lysis solution was removed from the slides and
placed in an alkaline solution to denature the DNA for
40 min at room temperature. Later, the slides were sub-
jected to TBE (Tris borate EDTA buffer) electrophoresis
for 10 min with 1 volt/cm current between the two elec-
trodes. Then the slides were fixed with 70% ethanol for
5 min, followed by SYBR green staining. The stained
slides were examined using an epifluorescent microscope
(Olympus BX51 TRF, USA). The data were analyzed with
DNA damage analysis software (Loats Associates Inc.,
USA). The control comet slides were prepared along with
the test comet slides under yellow light
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Western blot analysis was conducted to determine specific
cellular responses targeting apoptosis-related proteins in-
cluding Bax, cyt C and Bcl-2. HL-60 cells were treated
with different doses of ATO for 24 hr at 37°C. After incu-
bation, cells were washed twice with cold phosphate
buffered saline (PBS) and lysed in RIPA buffer containing
(1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS,
100 μg/ml phenylmethylsulfonyl fluoride, 100 μg/ml apro-
tinin, 1 μg/ml leupeptin, and 1 mm sodium orthovana-
date) on ice 20 min. It was centrifuged at 14000 rpm for
12 min and supernatant collected in fresh micro centri-
fuge tubes. The total protein of cells extracts contained in
the supernatant was measured by the Bradford method at
595 nm using a microtiter plate reader [29]. An equal
amount (40 μg) of protein from control or treated cells
was loaded per lane on a 10% SDS-PAGE gel, transferred
into nitrocellulose membrane and analyzed by Western
blotting for each specific protein of interest using its spe-
cific antibody as described previously [30]. The band in-
tensities were quantified using Image J (National Institutes
of Health).
Confocal microscopy for Bax and Cytochrome c
translocation
HL-60 cells (1×106 cells) were grown in presence or ab-
sence of ATO and further incubated with mitotracker
Red CMXRos (250 nM) for 30 min in dark at 37°C to
stain mitochondria. After staining, cells were washed
twice with PBS and adhered on poly- L- lysine coated
chambered slide. Cells were fixed by adding 3% parafor-
maldehyde solution and permeabilized with 0.2% Noni-
det P-40 in PBS containing glycine (0.5%). Cells were
blocked in PBS containing 3% BSA for 30 min, then in-
cubated with cytochrome C antibody (1:100 dilution) at
4°C overnight. Cells were washed with PBS and incu-
bated with Alex fluor 568 tagged secondary Ab (1:1000)
for 1 h at 4°C in dark. The cells were then incubated with
Hoechst 33342 with (1:1000) for 7 min in dark to stain the
nucleus. The cover slips were then mounted on slides
using 90% glycerol containing 0.025% PPD as antifade.
The images were acquired using the confocal microscope
(Olympus Company, Center valley, PA) at appropriate ex-
citation (578 nm) and emission (603 nm) wavelengths.
Caspase −3 activity assay
Caspase-3 activity was measured in cytosolic fraction of
control and ATO-treated HL-60 cells, using commercially
available kits and according to manufacturer protocol
(Sigma, St. Louis, MO, USA). In brief, cytosolic fraction of
cells from both control and ATO treated was prepared as
described earlier [31]. Equal amount of cytosolic proteins
were used for the assay of caspase 3 activity. Cytosolic
protein (50 μg) was mixed in a microtiter plate with assaybuffer and caspase specific substrates (Ac-DEVD-pNA for
caspase-3). After 4–16 h incubation at 37°C, the absorb-
ance of pNA released as a result of caspase-3 like activity
was measured at 405 nm in a microtiter plate reader as
described in technical bulletin. The absorbance of nega-
tive control (assay buffer substrate) was subtracted from
specific values. Mean values of triplicate measurements
were presented.
Measurement of change in mitochondrial membrane
potential (Δψm)
The integrity of the inner mitochondrial membrane may
be measured by observing the potential gradient across
this membrane. This can be achieved by measuring the
uptake of the cationic carbocyanine dye, JC1 into the
matrix. Mitochondria were isolated from control and
ATO-treated HL-60 cells using mitochondria isolation
kit (Sigma, St. Louis, MO, USA). Isolated mitochondria
were incubated with 2 μl JC1 stain (from stock 1 mg/ml)
and 950 μl JC1 assay buffer for 10 min in dark at 25°C.
The fluorescence of each sample (total assay vol. 1 ml)
was recorded using a Perkin Elmer LS50B spectrofluo-
rometer (excitation 490 nm, slit, 5 nm; emission 590 nm,
slit, 7.2 nm) [32].
Immunocytochemistry
HL-60 cells (1×105) were cultured in presence or ab-
sence of ATO and placed on poly-L-lysine coated slide.
Cells were fixed by using 3% paraformaldehyde and
permeablized with 0.2% NP-40 containing 0.5% glycine.
After blocking with 4% BSA, fixed cells were incubated
overnight with Ki-67 antibody (dilution, 1:100) (cat#
33–4711) from life technology company at 4°C. After in-
cubation, cells were washed with PBS three times and
tagged with secondary antibody (anti-mouse fluores-
cein) for one hour at room temperature followed by
Hoechst 33342 (dilution, 1:2000) staining 7 min. Slides
were washed with PBS and paste coverslip using pro-
long gold antifade reagent. After drying, slides were
imaged by confocal microscopy (Olympus company,
Center valley, PA).
Statistical analysis
Experiments were performed in triplicates. Data were
presented as means ± SDs. Where appropriate, one-way
ANOVA or student paired t-test was performed using
SAS Softwareavailable in the Biostatistics Core Laboratory
at Jackson State University. p-values less than 0.05 were
considered statistically significant.
Results
Arsenic trioxide induces oxidative stress in Hl-60 cells
In the present study we investigated three biomarkers
of oxidative stress including lipid peroxidation as
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cellular GSH content, and DNA damage in HL-60
cells following treatment with different doses of ATO.
Interestingly, ATO treatment significantly increased
MDA level (Figure 1A) as well as percentages of DNA
damage and Comet tail length (Figure 1C-E) in a dose-
dependent manner. Contrary, a significant decrease in
GSH content was observed at higher level of ATO expos-
ure (Figure 1B).Figure 1 Arsenic trioxide induces oxidative stress in HL-60 cells. (A) H
and the level of malondialdehyde(MDA) was measured by spectrophotome
means of three independent experiments ± SDs (# P < 0.05). (B) Cells were
level was measured by spectrophotometry at 412 nm. GSH was expressed
experiments ± SDs (##P < 0.05). (C) HL-60 cells were grown in absence or p
analyzed by alkaline Comet assay. (D) ATO – induced genotoxicity was exp
three independent experiments ± SDs (**P < 0.01). (E) ATO-induced comet
three independent experiments ± SDs (***P < 0.01).Arsenic trioxide modulates apoptotic proteins expression
ATO-induced oxidative stress in HL-60 cells also caused
an increase in the expression level of pro-apoptotic pro-
teins (Bax and cytochrome C) and reduced the expression
level of anti-apoptotic protein (Bcl-2), in a dose-dependent
manner (Figure 2A). Densitometric analysis has shown that
ATO-induced apoptotic proteins, cytchrome C and Bax
expression significantly (p < 0.05) increased at 4 and
6 μg/ml ATO treated HL-60 cells lysate (2B). Whereas,L-60 cells were incubated with 2, 4, 6 and 8 mg/ml of ATO for 24 hrs
try at 532 nm. MDA was expressed in nmole/ml. Data represent the
treated with different doses of ATO for 24 hrs and reduced GSH
in nmole GSH/ml. Data represent the means of three independent
resence of different doses of ATO for 24 hrs and DNA damage was
ressed as percentage of DNA damage. Data represent the means of
tail length was measured in micrometer. Data represent the means of
Figure 2 Arsenic trioxide modulates apoptotic proteins expression. (A) Western blots of intrinsic apoptotic pathway proteins in control and
ATO-treated HL-60 cells. ATO exposure significantly increased the expression levels of Bax, cytochrome C, and decreased the expression level of
Bcl-2 in a dose- dependent manner. (B) Densitometric analysis of ATO –induced apoptotic proteins expression in HL-60 cells. Data represent the
means of three independent experiments ± SDs (*p < 0.01; **p < 0.05 and #p < 0.01).
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cantly down regulated at 6 and 8 μg/ml ATO treatment
cells lysate (2B).
Arsenic trioxide changes inner mitochondrial membrane
potential
Due to imbalance ratio of Bax and Bcl-2 protein expres-
sion, ATO treatment lead to change in inner mitochon-
drial membrane potential and opening of transition
pores. We have measured this change in mitochondrial
membrane potential after treatment of cells with differ-
ent doses of ATO and by labeling with very sensitive cat-
ionic carbocynine dye, JC-1. In control sample, healthy
mitochondria showed high mitochondrial membrane po-
tential (ψm) with intact membrane and accumulated in
their matrix more JC-1 to form J- aggregates, showing
intense fluorescence at 590 nm. Whereas in ATO treatedcells, mitochondria showed lower ψm and less accumula-
tion of JC-1 in their matrix leading to less formation of J-
aggregates, and weak fluorescence at 590 nm (Figure 3A).
We have also done confocal microscopy imaging of con-
trol and ATO-treated cells followed by staining with JC-1
and DAPI. JC-1 monomer (530 nm) expression was acti-
vated by ATO treatment in a dose-dependent manner
[Figure 3B (i-v)].
Arsenic trioxide stimulates translocation of Bax and
Cytochrome C
Previous research has reported that oxidative stress acti-
vates translocation of pro-apoptotic proteins from cytosol
to mitochondria and release of cytochrome C from mito-
chondria to cytoplasm inside cell [33]. We have checked
ATO-induced translocation of pro-apoptotic protein, Bax
from cytosol to mitochondria and cytochrome C from
Figure 3 ATO changes mitochondrial membrane potential (Δψm). (A) ATO treatment was changed the mitochondrial membrane potential
in a dose- dependent manner. [(B)(i-v)] There are three subsets of each treatment-DAPI (blue), JC-1 monomer (excitation 530 nm, green) and
merged (blue/green). ATO treatment dose–dependently changed mitochondrial membrane potential and opened transition pores. It helped to
release J-aggregate and continuously increased JC-1 monomer (green color) in a dose dependent manner in HL-60 cells.
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Figure 4 (i-v) Arsenic trioxide stimulates translocation of Bax protein. Each image set contains four subsets, a - cells stained with DAPI (blue);
b – mitochondria stained with mitotracker red CMXRos (red, 250 nM); c – Bax protein tagged with fluorescent secondary antibody (green); and
d – merged image of all previous three (a, b and c). Both immunocytochemistry and confocal imaging show translocation of pro-apoptotic
protein, Bax from cytosol to mitochondria in a dose – dependent manner.
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Figure 5 Arsenic trioxide induces release of cytochrome C protein from mitochondria and activation of caspase 3. [(A) (i-v)] Each set
contains four subsets, a – cells stained with DAPI (blue); b- mitochondria stained with mitotracker red CMXRos (red, 250nM); c –cytochrome C
protein tagged with fluorescent secondary antibody (green); and d – merged image of all previous three (a, b and c). Here, it is shown that
cytochrome C was released from mitochondria in a dose- dependent manner. (B) Data also show a dose-dependent enhancement of caspase 3
activity with the ATO treatment of HL-60 cells.
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staining, mitochondria with mitotracker red and Bax as
well as cytochrome C protein with green fluorescent anti-
body. Our results show that the amount of translocated
Bax inside mitochondria [Figure 4 (i-v)] and cytochrome
C protein in cytosol of ATO treated HL-60 cells increased
in a dose-dependent manner [Figure 5A (i-v)]. We used
green fluorescent tag anti-Bax and anti-cytochrome C
antibody to recognize translocation of Bax and cyto-
chrome C by immunocytochemistry and confocal im-
aging of cells.
Arsenic trioxide stimulates Caspase-3 activity
Inside the cytosol, cytochrome C stimulates a series of
apoptotic signaling molecules along with variety of cas-
pases (like caspase 9) and finally caspase3 which is main
executioner of mitochondrial pathway of apoptosis [34].
We have investigated the caspase 3 activity in HL-60
cells following treatment with different doses of ATO.
Interestingly, ATO upregulatedcaspase 3 activity in a
dose-dependent manner (Figure 5B).
Discussion
Previous studies have reported that ATO diffuses through
cell membrane into the cytoplasm and produces cytotoxic
effect by generating reactive oxygen species. It has alsoFigure 6 ATO-induced intrinsic pathway of apoptosis in HL-60 cells. A
GSH content changed and DNA damage. It changes mitochondrial membr
proteins, which lead to caspase3 activity and apoptosis in HL-60 cells.been reported that ATO causes oxidative stress and cell
death in a variety of cells including acute promyelocyte
leukemia (APL), acute myeloid leukemia and chronic
myeloid leukemia as well as solid tumor cells in vitro [35],
but leukemia cells appear to be more susceptible and clin-
ical important than others [36]. Earlier studies have also
pointed out that lower doses of ATO induce cell prolifera-
tion, while higher doses inhibit growth in NB4 as well as
lymphoid malignant cells [21,37]. ATO has also been
found to inhibit DNA synthesis in human colon cancer
cells [15] and proliferation in myeloma cell lines dose –
dependent manner [12]. Recently, several groups have
provided evidence that ATO induces cell cycle arrest and
apoptosis in a variety of leukemia as well as myeloma cells
[12,38]. But the detailed mechanisms of toxicity to HL-60
cells mostly remain unknown. Here, we have elucidated
the molecular mechanisms ATO-induced oxidative stress
and intrinsic pathway of apoptosis in HL-60 cells. Our
findings indicate that ATO causes oxidative stress through
generation of ROS, increase in lipid peroxidation, induc-
tion of DNA damage and reduction of GSH level in HL-
60 cells (Figure 1A-E).
Accumulating data have suggested that ATO - induced
apoptosis is associated with down-regulation of Bcl-2 pro-
tein in NB4 cells [22] and activation of Bax protein ex-
pression as well as reduction of mitochondrial membraneTO induces oxidative stress in APL cells through lipid peroxidation,
ane potential and modulates expression and translocation of apoptotic
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here reveal that ATO activated Bax and cytochrome C ex-
pression and down-regulated Bcl-2 protein expression in
HL-60 cells in a dose-dependent manner (Figure 2A & B).
ATO-induced oxidative stress and alteration of Bax and
Bcl-2 proteins expression lead to change in mitochon-
drial membrane potential of HL-60 cells. In ATO-
treated cells, we found that a significant decrease in
mitochondrial membrane potential and increase in JC-
1-monomer (green color) in a dose-dependent manner
(Figure 3A-B). It has also been reported from other
studies that oxidative stress stimulates translocation of
Bax from cytosol to mitochondria and release of cyto-
chrome C inside cytoplasm during liver apoptosis [33].
Other research groups have reported that ATO-induced
apoptosis is associated with Bax translocation in cer-
vical cancer cells [40], and release of cytochrome C from
mitochondria in lymphoma B-cells [39]. Our results
support these findings showing that ATO induces trans-
location ofBax and cytochrome in HL-60 cells a dose-
dependent manner [Figure 4 (i-v) and 5A (i-v)]. Inside
the cytosol, cytochrome C seems to activate different
signaling molecules along with a variety of caspases and
finally caspase 3 in the intrinsic pathway of apoptosis.
Other studies have demonstrated the role of caspase 3
in chemical-induced apoptosis. Cellfood™ induces apop-
tosis in leukemia cell lines (U937, Jurkat) through caspase-
3 activation and DNA fragmentation [41]. Cinnamic acid
also causes apoptosis in melanoma cells (HT-144) by
caspase-3 activation and DNA damage [42]. Baicalin in-
duces intrinsic pathway of apoptosis in lymphoma cells via
DNA fragmentation, modulation of apoptotic and caspase-
3 proteins expression [43]. Interestingly, we found that
ATO treatment increased caspase 3-activity in a dose-
dependent manner (Figure 4B). ATO as a genotoxic com-
pound induces clastogenic effect in HL-60 cells through
oxidative DNA damage and oxidative stress in a dose
dependent manner. ATO has been reported to inhibit
unscheduled DNA synthesis in V79 Chinese hamster
cells by excision of pyrimidine dimmers [44]. Erlotinib,
an inhibitor of EGFR enhances ATO mediated DNA
double –strand break/damage by preventing EGFR –
mediated DNA double-strand break repair human A549
lung cancer cells [45]. ATO – induced oxidative stress
produces epigenetic effect through specific DNA base
modification on exposure of mammalian cells and produc-
tion of 8-hydroxy-2'-deoxyguanosine (8-OHdG) [46]. It is
shown to increase oxidative DNA damage product, 8-
OHdG in acute promyelocytic leukemia patients during
arsenic therapy [47]. ATO causes apoptosis in multiple
myeloma cells by disruption of mitochondrial membrane
potential and caspase-3 activity [48]. It also induces apop-
tosis in lymphoid neoplasms through cell cycle arrest
[21,49], as well as in plasma cells from myeloma patients[50]. ATO induces apoptosis in NB4 cells through down-
regulation of Bcl-2 expression and modulation of PML-
RARα/PML proteins [22]. Similar to Domoic acid and
Okadaic acid (natural toxicants) [51], ATO bears both
genotoxic and epigenetic properties. Taken together, we
have demonstrated from our research that ATO induces
mitochondrial pathway of apoptosis through oxidative
stress; modulating expression and translocation of
apoptotic proteins, and changing inner mitochondrial
membrane potential and caspase 3 activity in HL-60
cells (Figure 6).
Conclusions
It can be concluded from the present in vitro study that
arsenic trioxide induces mitochondrial pathway of apop-
tosis in HL-60 cells. Although the exact anti-leukemic
molecular mechanism of ATO is not well understood,
we have investigated in present study its detailed mech-
anism of oxidative stress-induced intrinsic pathway of
apoptosis by modulation of expression and translocation
of apoptotic proteins, changing mitochondrial mem-
brane potential and activation of caspase 3 activity in
HL-60 cells. By elucidating the anti-leukemic mecha-
nisms of action of ATO in HL-60 cells, we are able to
provide new insights into the molecular targets, and a
rational basis for drug designing for a more prominent
APL chemotherapy in the future.
Abbreviations
ANOVA: One way analysis of variance; APL: Acute promyelocytic leukemia;
ATO: Arsenictrioxide; ATRA: All trans retinoic acid; DMSO: Dimethylsulfoxide;
DNA: Deoxyribonucleic acid; FACS: Fluorescenceactivated cell sorting system;
MDA: Malondialdehyde; MTT: 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-
2tetrazoliumbromide; PBS: Phosphate buffer saline; ROS: Reactive oxygen
species.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SK and PBT conceived, designed and implemented the study, and drafted
the manuscript.CGY participated in the implementation of research activities.
All authors read and approved the final draft of the manuscript.
Acknowledgments
The research described in this publication was made possible by a grant
from the National Institutes of Health (Grant No. G12MD007581) through the
RCMI Center for Environmental Health at Jackson State University.
Received: 26 March 2014 Accepted: 11 May 2014
Published: 16 May 2014
References
1. Powell BL: Arsenic trioxide in acute promyelocytic leukemia: potion not
poison. Expert Rev Anticancer Ther 2011, 11:1317–1319.
2. Jemal A, Thomas A, Murray T, Thun M: Cancer statistics. CA Cancer J Clin
2002, 52:23–47.
3. Yedjou C, Tchounwou P, Jenkins J, McMurray R: Basic mechanisms of
arsenic trioxide (ATO)-induced apoptosis in human leukemia (HL-60)
cells. J Hematol Oncol 2010, 3:28–35.
4. Stone RM, Maguire M, Goldberg M: Complete remission in acute
promyelocytic leukemia despite persistence of abnormal bone marrow
Kumar et al. Journal of Experimental & Clinical Cancer Research 2014, 33:42 Page 11 of 12
http://www.jeccr.com/content/33/1/42promyelocytes during induction therapy: experience in 34 patients.
Blood 1988, 71:690–696.
5. Kantarjian HM, Keating MJ, Walters RS: Acute promyelocytic leukemia. M.
D. Anderson Hospital experience. Am J Med 1986, 80:789–797.
6. Gallagher RE: Retinoic acid resistance in acute promyelocytic leukemia.
Leukemia 2002, 16:1940–1958.
7. Soignet SL, Frankel SR, Douer D: United States multicenter study of
arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol
2001, 19:3852–3860.
8. Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F,
Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W,
Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM,
Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M,
Lübbert M, Hänel M, Schmitz N, et al: Retinoic acid and arsenic trioxide for
acute promyelocytic leukemia. N Engl J Med 2013, 369:111–121.
9. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D,
DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP, Warrell RP Jr: Complete
remission after treatment of acute promyelocytic leukemia with arsenic
trioxide. N Engl J Med 1998, 339:1341–1348.
10. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, Rostami S, Jahani M,
Hosseini R, Mossavi A, Baybordi E, Khodabadeh A, Iravani M, Bahar B,
Mortazavi Y, Totonchi M, Aghdami N: Treatment of acute promyelocytic
leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann
Oncol 2006, 17:131–134.
11. Ghavamzadeh A, Alimoghaddam K, Rostami S, Ghaffari SH, Jahani M,
Iravani M, Mousavi SA, Bahar B, Jalili M: Phase II study of single-agent
arsenic trioxide for the front-line therapy of acute promyelocytic
leukemia. J Clin Oncol 2011, 29:2753–2757.
12. Park WH, Seol JG, Kim ES, Hyun JM, Jung CW, Lee CC, Kim BK, Lee YY:
Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells
via cell cycle arrest in association with induction of cyclin-dependent
kinase inhibitor, p21, and apoptosis. Cancer Res 2000, 60:3065–3071.
13. Soriano C, Creus A, Marcos R: Arsenic trioxide mutational spectrum
analysis in the mouselymphoma assay. Mutat Res 2008, 646:1–7.
14. Patlolla AK, Tchounwou PB: Cytogenetic evaluation of arsenic trioxide
toxicity in Sprague–Dawley rats. Mutat Res 2005, 587:126–133.
15. Stevens JJ, Graham B, Walker AM, Tchounwou PB, Rogers C: The effects of
arsenic trioxideon DNA synthesis and genotoxicity in human colon
cancer cells. Int J Environ Res Public Health 2010, 7:2018–2032.
16. Jiang XH, Wong BC, Yuen ST, Jiang SH, Cho CH, Lai KC, Lin MC, Kung HF,
Lam SK: Arsenic trioxide induces apoptosis in human gastric cancer cells
through up-regulation of p53 and activation of caspase-3. Int J Cancer
2001, 91:173–179.
17. Tchounwou PB, Yedjou CG, Dorsey WC: Arsenic trioxide-induced
transcriptional activation and expression of stress genes in human liver
carcinoma cells (HepG2). Cell Mol Biol (Noisy-le-Grand) 2003, 49:1071–1079.
18. Alarifi S, Ali D, Alkahtani S, Siddiqui MA, Ali BA: Arsenic trioxide-mediated
oxidative stress and genotoxicity in human hepatocellular carcinoma
cells. Onco Targets Ther 2013, 6:75–84.
19. Wang ZG, Rivi R, Delva L, König A, Scheinberg DA, Gambacorti-Passerini C,
Gabrilove JL, Warrell RP Jr, Pandolfi PP: Arsenic trioxide and melarsoprol
induce programmed cell death in myeloid leukemia cell lines and function
in a PMLand PML-RARa independent manner. Blood 1998, 92:1497–1504.
20. Akao Y, Mizoguchi H, Kojima S, Naoe T, Ohishi N, Yagi K: Arsenic induces
apoptosis in B-cell leukemic cell lines in vitro: activation of caspases and
down-regulation of Bcl-2 protein. Br J Haematol 1998, 102:1055–1060.
21. Zhang W, Ohnishi K, Shigeno K, Fujisawa S, Naito K, Nakamura S, Takeshita
K, Takeshita A, Ohno R: The induction of apoptosis and cell cycle arrest
by arsenic trioxide in lymphoid neoplasms. Leukemia 1998, 12:1383–1391.
22. Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, Jin XL, Tang W, Li XS, Xong
SM, Shen ZX, Sun GL, Ma J, Zhang P, Zhang TD, Gazin C, Naoe T, Chen SJ,
Wang ZY, Chen Z: In vitro studies on cellular and molecular mechanisms of
arsenic trioxide As2O3 in the treatment of acute promyelocytic leukemia:
As2O3 induces NB4 cell apoptosis with down-regulation of Bcl-2 expression
and modulation of PML-RARa/PML proteins. Blood 1996, 88:1052–1061.
23. Cai X, Yu Y, Huang Y, Zhang L, Jia PM, Zhao Q, Chen Z, Tong JH, Dai W,
Chen GQ: Arsenic trioxide-induced mitotic arrest and apoptosis in acute
promyelocytic leukemia cells. Leukemia 2003, 17:1333–1337.
24. Collins SJ, Ruscetti FW, Gallagher RE, Gallo RC: Terminal differentiation of
human promyelocytic leukemia cells induced by dimethyl sulfoxide and
other polar compounds. Proc Natl Acad Sci U S A 1978, 75:2458–2462.25. Kumar S, Guha M, Choubey V, Maity P, Srivastava SK, Bandyopadhyay U:
Bilirubin inhibits Plasmodium falciparum growth through the generation
of reactive oxygen species. Free Radic Biol Med 2008, 44:602–613.
26. Singh NP, McCoy MT, Tice RR, Schneider EL: A simple technique for
quantitation of low levels of DNA damage in individual cells. Exp Cell Res
1988, 175:184–191.
27. Yedjou CG, Tchounwou PB: In-vitro cytotoxic and genotoxic effects of
arsenic trioxide on human leukemia (HL-60) cells using the MTT and
alkaline single cell gel electrophoresis (Comet) assays. Mol Cell Biochem
2007, 301:123–130.
28. Velma V, Tchounwou PB: Oxidative stress and DNA damage induced by
chromium in liver and kidney of goldfish, carassius auratus. Biomark
Insights 2013, 8:43–51.
29. Bradford MM: A rapid and sensitive method for the quantitation of
microgram quantities of protein utilizing the principle of protein-dye
binding. Anal Biochem 1976, 72:248–254.
30. Singh NK, Kundumani-Sridharan V, Kumar S, Verma SK, Kotla S, Mukai H,
Heckle MR, Rao GN: Protein kinase N1 is a novel substrate of
NFATc1-mediated cyclin D1-CDK6 activity and modulates vascular
smooth muscle cell division and migration leading to inward blood
vessel wall remodeling. J Biol Chem 2012, 287:36291–36304.
31. Wissing D, Mouritzen H, Jaattela M: TNF-induced mitochondrial changes
and activation of apoptotic proteases are inhibited by A20. Free Radic
Biol Med 1998, 25:57–65.
32. Cossarizza A, Baccarani-Contri M, Kalashnikova G, Franceschi C: A new method
for the cytofluorimetric analysis of mitochondrial membrane potential
using the Jaggregate forming lipophilic cation 5,5_,6,6_-tetrachloro-1,1_,3,
3_-tetraethylbenzimidazolcarbocyanine iodide (JC-1). Biochem Biophys Res
Commun 1993, 197:40–45.
33. Guha M, Kumar S, Choubey V, Maity P, Bandyopadhyay U: Apoptosis in
liver during malaria: role of oxidative stress and implication of
mitochondrial pathway. FASEB J 2006, 20:1224–1226.
34. Chattopadhyay S, Fensterl V, Zhang Y, Veleeparambil M, Yamashita M,
Sen GC: Role of interferon regulatory factor 3-mediated apoptosis in the
establishment and maintenance of persistent infection by Sendai virus.
J Virol 2013, 87:16–24.
35. Uslu R, Sanli UA, Sezgin C, Karabulut B, Terzioglu E, Omay SB: Arsenic
trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian
carcinoma cell lines. Clin Cancer Res 2000, 6:4957–4964.
36. Jang M, Kim Y, Won H, Lim S, KRJ, Dashdorj A, Min YH, Kim SY, Shokat KM,
Ha J, Kim SS: Carbonyl reductase 1 offers a novel therapeutic target to
enhance leukemia treatment by arsenic trioxide. Cancer Res 2012,
72:4214–4224.
37. Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, Han ZG, Ni JH, Shi GY,
Jia PM, Liu MM, He KL, Ma J, Zhang P, Zhang TD, Paul P, Naoe T, Kitamura K,
Miller W, Waxman S, Wang ZY, de The H, Chen SJ, Chen Z: Use of arsenic
trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL):
I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 1997,
89:3345–3353.
38. Ma DC, Sun YH, Chang KZ, Ma XF, Huang SL, Bai YH, Kang J, Liu YG, Chu JJ:
Selective induction of apoptosis of NB4 cells from G2 + M phase by
sodium arsenite at lower doses. Eur J Haematol 1998, 61:27–35.
39. Baysan A, Yel L, Gollapudi S, Su H, Gupta S: Arsenic trioxide induces
apoptosis via the mitochondrial pathway by upregulating the expression
of Bax and Bim in human B cells. Int J Oncol 2007, 30:313–318.
40. Kang YH, Lee SJ: The role of p38 MAPK and JNK in arsenic trioxide-induced
mitochondrial cell death in human cervical cancer cells. J Cell Physiol 2008,
217:23–33.
41. Catalani S, Carbonaro V, Palma F, Arshakyan M, Galati R, Nuvoli B,
Battistelli S, Canestrari F, Benedetti S: Metabolism modifications and
apoptosis induction after Cellfood™ administration to leukemia cell lines.
J Exp Clin Cancer Res 2013, 32:63.
42. Niero EL, Machado-Santelli GM: Cinnamic acid induces apoptotic cell
death and cytoskeleton disruption in human melanoma cells. J Exp Clin
Cancer Res 2013, 32:31.
43. Huang Y, Hu J, Zheng J, Li J, Wei T, Zheng Z, Chen Y: Down-regulation of
the PI3K/Akt signaling pathway and induction of apoptosis in CA46
Burkitt lymphoma cells by baicalin. J Exp Clin Cancer Res 2012, 31:48.
44. Okui T, Fujiwara Y: Inhibition of human excision DNA repair by inorganic
arsenic and the comutageniceffect in V79 Chinese hamster cells.
Mutat Res 1986, 172:69–76.
Kumar et al. Journal of Experimental & Clinical Cancer Research 2014, 33:42 Page 12 of 12
http://www.jeccr.com/content/33/1/4245. Kryeziu K, Jungwirth U, Hoda MA, Ferk F, Knasmüller S, Karnthaler-Benbakka C,
Kowol CR, Berger W, Heffeter P: Synergistic anticancer activity of arsenic
trioxide with erlotinib is based on inhibition of EGFR-mediated DNA
double-strand break repair. Mol Cancer Ther 2013, 12:1073–1084.
46. Kessel M, Liu SX, Xu A, Santella R, Hei TK: Arsenic induces oxidative DNA
damage in mammalian cells. Mol Cell Biochem 2002, 234–235:301–308.
47. Ninomiya M, Kajiguchi T, Yamamoto K, Kinoshita T, Emi N, Naoe T:
Increased oxidative DNA products in patients with
acutepromyelocyticleukemia during arsenic therapy. Haematologica 2006,
91:1571–1572.
48. Jia P, Chen G, Huang X, Cai X, Yang J, Wang L, Zhou Y, Shen Y, Zhou L,
Yu Y, Chen S, Zhang X, Wang Z: Arsenic trioxide induces multiple
myeloma cell apoptosis via disruption of mitochondrial transmembrane
potentials and activation of caspace-3. Chin Med J (Engl) 2001, 114:19–24.
49. Lu M, Levin J, Sulpice E, Sequeira-Le Grand A, Alemany M, Caen JP, Han ZC:
Effect of arsenic trioxide on viability, proliferation, and apoptosis in
human megakaryocytic leukemia cell lines. Exp Hematol 1999, 27:845–852.
50. Rousselot P, Labaume S, Marolleau JP, Larghero J, Noguera MK, Brouet JC,
Fermand JP: Arsenic trioxide and melarsoprol induce apoptosis in plasma
cell lines and in plasma cellsfrom myeloma patients. Cancer Res 1999,
59:1041–1048.
51. Carvalho PS, Catian R, Moukha S, Matias WG, Creppy EE: Comparative study
of domoic acid and okadaic acid induced -chromosomal abnormalities
in the CACO-2 Cell Line. Int J Environ Res Public Health 2006, 3:4–10.
doi:10.1186/1756-9966-33-42
Cite this article as: Kumar et al.: Arsenic trioxide induces oxidative stress,
DNA damage, and mitochondrial pathway of apoptosis in human
leukemia (HL-60) cells. Journal of Experimental & Clinical Cancer Research
2014 33:42.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
